Back to Sites Umlazi Clinical Research Site Site Number 30300 Address Umlazi CRS 1358 Mangosuthu Highway Umlazi, KwaZulu-Natal, 4066 South Africa IMPAACT Members at this Site Balungile Myeza CAB Member (not CRS Staff) Thumbi Ndung'u Co-Investigator Thandeka Nkosi Community Coordinator Scebi Nkosi Counselor Zukiswa Godlwana CRS Coordinator Dhayendre Moodley CRS Leader Zakir Gaffoor BS MMSc CTU Coordinator Quarraisha Abdool Karim CTU Principal Investigator Blanca Castillo DAIDS PO Eileen Pouliot DAIDS PO Linda Ngaleka Data Manager Moherndran Archary Investigator Hoosen Coovadia Investigator Kogieleum Naidoo Investigator Michelle Singh Investigator Natasha Samsunder Laboratory Director Natasha Samsunder Laboratory Manager/Supervisor Yurana Valjee Laboratory Technician Sylvano (Selven) Pillay Local Laboratory Devan Govender N/A Alicia Desmond Pharmacist Thusie Pather QA/QC Coordinator Natasha Pillay QA/QC Coordinator Vanessa Tombe Regulatory Coordinator Salim Karim Site Leader Studies at this Site P1084s: Maternal Infant TDF Toxicity Safety DAIDS Number 10790 Research Area Therapeutics Study Status Closed to Follow Up P1090: Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine DAIDS Number 10850 Research Area Treatment Study Status Concluded P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed 1077BF: PROMISE 1077BF DAIDS Number 10777 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed P1110: Safety and PK of RAL in Neonates DAIDS Number 11891 Research Area Treatment Study Status Concluded P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure and Immunotherapy Study Status Enrolling IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Concluded IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling Pagination Current page 1 Page 2 Next page Next
P1084s: Maternal Infant TDF Toxicity Safety DAIDS Number 10790 Research Area Therapeutics Study Status Closed to Follow Up
P1090: Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine DAIDS Number 10850 Research Area Treatment Study Status Concluded
P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
1077BF: PROMISE 1077BF DAIDS Number 10777 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed
P1110: Safety and PK of RAL in Neonates DAIDS Number 11891 Research Area Treatment Study Status Concluded
P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure and Immunotherapy Study Status Enrolling
IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Concluded
IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling